Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, General Counsel | June 22, 2020 | June 23, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Operating Officer | January 29, 2026 | April 21, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Legal Officer | February 02, 2012 | February 06, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,871 |
Ending reported balance
After 2020-06-22 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2020-06-22 · Exercise / conversion · Acquired 1,280 · Balance 33,151 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 2 · 2020-06-22 · Exercise / conversion · Acquired 1,858 · Balance 35,009 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 3 · 2020-06-22 · Exercise / conversion · Acquired 56,984 · Balance 91,993 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 4 · 2020-06-22 · Exercise / conversion · Acquired 45,000 · Balance 136,993 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 5 · 2020-06-22 · Sale · Disposed 6,009 · Balance 130,984 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2020-06-22 · Sale · Disposed 8,086 · Balance 122,898 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2020-06-22 · Sale · Disposed 35,757 · Balance 87,141 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2020-06-22 · Sale · Disposed 55,270 · Balance 31,871 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-06-22 · Exercise / conversion · Disposed 1,280 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-06-22 · Exercise / conversion · Disposed 1,858 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2022-11-05 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-06-22 · Exercise / conversion · Disposed 56,984 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.03 · Expires 2024-02-28 | Direct | 7,708 |
Reported balance
After 2020-06-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-06-22 · Exercise / conversion · Disposed 45,000 · Balance 7,708 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Solid Biosciences Inc.
Report date January 29, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 79,341 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 79,341 · Balance 79,341 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
VERTEX PHARMACEUTICALS INC / MA
Report date February 02, 2012 · Filed February 06, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,437 |
Reported balance
After 2012-02-02 transaction · row 1
1 source rowRow 1 · 2012-02-02 · Grant · Acquired 10,166 · Balance 19,437 F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $37.86 · Expires 2022-02-01 | Direct | 68,750 |
Reported balance
After 2012-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-02-02 · Grant · Acquired 68,750 · Balance 68,750 F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 266 |
Reported balance
Holding disclosure · report date 2012-02-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 266 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.
F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2018 Filed Mar 16, 2018 22:12 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 23 | $13.71 | $315.33 |
DisclosureSEC source: 0001209191-18-020353 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017791 · doc4.xml · derivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-03-05 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 10,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047898 · doc4.xml · derivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. F3 · derivative.expiration_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,642 | $37.88 | $175,838.96 |
DisclosureSEC source: 0001209191-17-047898 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,298 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:40 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047898 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 676 | $23.85 Strike: $23.85 | $16,122.60 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · derivative · entry 10 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,092 Underlying: Common Stock · 676 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: 25% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 324 | $13.71 Strike: $13.71 | $4,442.04 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · derivative · entry 9 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93 Underlying: Common Stock · 324 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Half of the options begin vesting in the event the FDA provides marketing approval for eteplirsen as of the applicable PDUFA date and the other half of the options begin vesting in the event Sarepta files a Marketing Authorization Application with the EMEA prior to December 31, 2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vests immediately upon achievement of the performance condition (25% of the total Performance-Based Options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total Performance-Based Options granted) vests over four years with 25% of these remaining options vesting on the first year anniversary of the grant date and 1/48th of these remaining options vesting monthly thereafter. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 676 | $23.85 | $16,122.60 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · nonDerivative · entry 6 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 324 | $13.71 | $4,442.04 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 5,944 | $13.71 Strike: $13.71 | $81,492.24 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · derivative · entry 8 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,146 Underlying: Common Stock · 5,944 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 19,056 | $13.71 Strike: $13.71 | $261,257.76 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · derivative · entry 7 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,527 Underlying: Common Stock · 19,056 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 5,944 | $41.00 | $243,704.00 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,301 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,944 | $13.71 | $81,492.24 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 19,056 | $41.00 | $781,296.00 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,301 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 19,056 | $13.71 | $261,257.76 |
DisclosureSEC source: 0001209191-17-046036 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| March 19, 2017 Filed Mar 21, 2017 22:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 152 | $30.30 | $4,605.60 |
DisclosureSEC source: 0001209191-17-022110 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,301 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantIncentive Stock Option (right to buy) · Derivative | 4,411 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020690 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411 Underlying: Common Stock · 4,411 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,589 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020690 · doc4.xml · derivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,589 Underlying: Common Stock · 25,589 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-16-149230 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,768 Underlying: Common Stock · 1,000 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option granted became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,000 | $23.85 | $23,850.00 |
DisclosureSEC source: 0001209191-16-149230 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:19 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 7,000 | $13.90 Strike: $13.90 | $97,300.00 |
DisclosureSEC source: 0001209191-16-142780 · doc4.xml · derivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,007 Underlying: Common Stock · 7,000 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:19 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 7,000 | $60.00 | $420,000.00 |
DisclosureSEC source: 0001209191-16-142780 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,453 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:19 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 7,000 | $13.90 | $97,300.00 |
DisclosureSEC source: 0001209191-16-142780 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:28 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 8,000 | $13.90 Strike: $13.90 | $111,200.00 |
DisclosureSEC source: 0001209191-16-142355 · doc4.xml · derivative · entry 6 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,007 Underlying: Common Stock · 8,000 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:28 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,304 | $50.00 | $65,200.00 |
DisclosureSEC source: 0001209191-16-142355 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,453 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:28 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 19,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142355 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,757 F3 · shares: 15,300 RSAs vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, with an additional 3,825 RSAs vesting during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:28 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 464 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142355 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 F2 · shares: 100% of the Restricted Stock Award ("RSA") granted on September 19, 2016 vests six months from the date of grant. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:28 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 8,000 | $50.00 | $400,000.00 |
DisclosureSEC source: 0001209191-16-142355 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,168 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:28 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 8,000 | $13.90 | $111,200.00 |
DisclosureSEC source: 0001209191-16-142355 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 68,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007772 · doc4.xml · derivative · entry 3 Howton David T · CIK 0001529297 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Underlying: Common Stock · 68,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007772 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,437 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| September 01, 2011 Filed Sep 7, 2011 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 328 | $44.29 | $14,527.12 |
DisclosureSEC source: 0001209191-11-046867 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,271 F1 · kind: Transaction made pursuant to Mr. Howton's company approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.